Back

Cardiotoxicity risk assessment using HFA-ICOS score: a cross-sectional analysis of patients with breast cancer undergoing chemotherapy or anti-HER2 therapies in a tertiary care center

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Scores (2) Scores ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Laura Paez Zamora

Los Cobos Medical Center, Bogota (Colombia)

7 More presentations in this session

Presentation thumbnail
Leukocyte trajectories and cardiovascular events in individuals with and without carotid plaque: a community cohort study
Doctor J. Yang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Cardiovascular-kidney-metabolic syndrome in korean: a nationwide stage-specific epidemiology and risk of major adverse cardiovascular events
Professor W. Pyun (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Validation and comparison of SCORE2-Diabetes and ASCVD score in Japanese patients with diabetes without a history of cardiovascular disease
Doctor Y. Nakamura (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Validation of the pathobiological determinants of atherosclerosis in youth risk score in a Norwegian cohort of young adults
Ms B. Lutterbey (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Epicardial adipose tissue thickness as an early predictor of metabolic syndrome in young women with BMI <30
Doctor A. Erdem (Istanbul, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Scores (2)

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
Clinical application of the HFA/ICOS score in breast cancer women: its added value in the prediction of chemotherapy-related cardiac dysfunction
thumbnail
Congress Presentation
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources